RUBY — Rubius Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Rubius Therapeutics Reports First Quarter 2022 Financial Results
Rubius Therapeutics Inc expected to post a loss of 58 cents a share - Earnings Preview
Rubius Therapeutics hits record low as lead drug's data continues to weigh
U.S. RESEARCH ROUNDUP-Datto Holding, Hashicorp, Tenable Holdings
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:37 AM
Brokerages cut PT for Rubius as lead drug's data disappoints
U.S. RESEARCH ROUNDUP- Astec Industries, ChampionX, Schlumberger NV
Rubius Therapeutics plunges as lead drug's cancer trial data disappoints
NASDAQ RESUMED AT 01:21 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:17 PM
Rubius Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Rubius Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Rubius Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: Rubius Therapeutics Announces Dosing Of First Patient In Phase 1/2 Trial Of RTX-224 For The Treatment Of Certain Solid Tumors
Rubius Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Rubius Therapeutics Posts Q3 Loss Per Share Of $0.55
Brief: Rubius Therapeutics Reports Q2 Results
Rubius Therapeutics Inc reports results for the quarter ended in June - Earnings Summary